SEC Form POS AM filed by Liminal BioSciences Inc.

$LMNL
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $LMNL alert in real time by email
POS AM 1 d457639dposam.htm POS AM POS AM

As filed with the Securities and Exchange Commission on September 26, 2023

Registration No. 333-245703

Registration No. 333-251055

Registration No. 333-251065

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Post-Effective Amendment No. 2 to

FORM F-3 Registration No. 333-245703

Post-Effective Amendment No. 1 to

FORM F-3 Registration No. 333-251055

FORM F-3 Registration No. 333-251065

UNDER

THE SECURITIES ACT OF 1933

 

 

LIMINAL BIOSCIENCES INC.

(Exact name of registrant as specified in its charter)

 

 

 

Canada   Not applicable

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

440 Armand-Frappier Boulevard,

Suite 300

Laval, Quebec

H7V 4B4

Tel: +1 450 781 0115

(Address, including zip code, and telephone number, including area code, of principal executive offices)

 

 

Bruce Pritchard

Chief Executive Officer

Liminal BioSciences Inc.

440 Armand-Frappier Boulevard,

Suite 300

Laval, Quebec

H7V 4B4

(Name and address of agent for service)

 

 

Tel: +1 450 781 0115

(Telephone number, including area code, of agent for service)

 

 

Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this registration statement.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 

 


DEREGISTRATION OF SECURITIES

This Post-Effective Amendment (this “Post-Effective Amendment”), filed by Liminal BioSciences Inc., a corporation existing under the laws of Canada (the “Company”), relates to the following Registration Statements on Form F-3 (each a “Registration Statement” and collectively, the “Registration Statements”) (note that the share numbers listed below do not take into account corporate actions, such as stock splits, taken in the interim):

 

   

Registration Statement on Form F-3 (No. 333-245703) filed by the Company with the Securities and Exchange Commission (the “SEC”) on August 13, 2020, registering (a) up to 20,160,241 shares of the Company’s common shares, no par value per share (“Common Shares”) and (b) an indeterminate number of shares of additional Common Shares.

 

   

Registration Statement on Form F-3 (No. 333-251055) filed by the Company with the SEC on December 1, 2020, registering an indeterminate number of (a) Common Shares, (b) debt securities, (c) warrants to purchase Common Shares, (d) rights to purchase any securities of the Company, and (g) units consisting of the Company’s Common Shares, rights, warrants or any combination of such securities, with an aggregate maximum offering price of all securities sold pursuant to such registration statement not to exceed $200 million;

 

   

Registration Statement on Form F-3 (No. 333-251065) filed by the Company with the SEC on December 1, 2020, registering up to 14,210,522 Common Shares, with an aggregate maximum offering price for all securities sold pursuant to such registration statement not to exceed $57,552,614.10.

The Company entered into that certain Plan of Arrangement, dated as of July 11, 2023, by and among the Company and Structured Alpha LP, a limited partnership existing under the laws of the Cayman Islands (“SALP”), pursuant to which SALP acquired directly or indirectly all of the issued and outstanding Common Shares of the Company not previously owned by SALP or its affiliates and associates at a price of US$8.50 per Common Share, payable in cash and the Company became a wholly-owned subsidiary of SALP (the “Arrangement”). The Arrangement was completed on September 26, 2023.

As a result of the Arrangement, the offerings contemplated by the Registration Statements have been terminated as of the date hereof. In accordance with the undertakings contained in the Registration Statements to remove from registration by means of a post-effective amendment any of the securities registered under the Registration Statements that remain unsold at the termination of the offerings, the Company hereby removes from registration any and all securities registered but unsold under the Registration Statements as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, and Rule 478 thereunder, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-3 and has duly caused this Post-Effective Amendment to be signed on its behalf by the undersigned, thereunto duly authorized, in Laval, Quebec, on September 26, 2023.

 

LIMINAL BIOSCIENCES INC.

By:   /s/ Bruce Pritchard
 

Name:

 

Bruce Pritchard

 

Title:

 

Chief Executive Officer

Note: No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act, as amended.

Get the next $LMNL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LMNL

DatePrice TargetRatingAnalyst
6/24/2021Buy → Neutral
H.C. Wainwright
More analyst ratings

$LMNL
Press Releases

Fastest customizable press release news feed in the world

See more
  • LIMINAL BIOSCIENCES ANNOUNCES COMPLETION OF THE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP

    LAVAL, QC and CAMBRIDGE, England, Sept. 26, 2023 /PRNewswire/ - Liminal BioSciences Inc. ("Liminal BioSciences" or the "Company") is pleased to announce that the transaction contemplated by the previously announced statutory plan of arrangement under the provisions of the Canada Business Corporations Act involving the Corporation and Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd., was completed earlier today (the "Arrangement"). Pursuant to the Arrangement, SALP acquired all of the issued and outstanding common shares of Liminal BioSciences (the "Shares") not currently owned by SALP or its affiliates and associates (the "Min

    $LMNL
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • LIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP

    LAVAL, QC and CAMBRIDGE, England, Sept. 19, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that it received the final order of the Ontario Superior Court of Justice (Commercial List) approving the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd., will acquire all of the issued and outstanding common shares of Liminal BioSciences (the "Shares") not currently owned by SALP or its affiliates and associates at a price o

    $LMNL
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • LIMINAL BIOSCIENCES SHAREHOLDERS APPROVE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP

    LAVAL, QC and CAMBRIDGE, England, Sept. 15, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that its shareholders have approved the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd., will acquire all of the issued and outstanding common shares of Liminal BioSciences (the "Shares") not currently owned by SALP or its affiliates and associates at a price of US$8.50 per Share, payable in cash (the "Arrangement"). Further

    $LMNL
    Biotechnology: Pharmaceutical Preparations
    Health Care

$LMNL
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$LMNL
SEC Filings

See more

$LMNL
Leadership Updates

Live Leadership Updates

See more
  • Liminal BioSciences Announces Voting Results of its 2023 Annual General Meeting of Shareholders

    LAVAL, QC and CAMBRIDGE, England, June 5, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General Meeting of Shareholders ("AGM") held virtually on June 5, 2023. A total of 2,235,519 common shares were voted, representing 72.02% of the votes attached to the issued and outstanding common shares of Liminal BioSciences. Election of Directors of the CompanyThe six (6) nominees set forth in the Circular were elected as directors of the Company to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. Name of Nominee For Against  Votes % Votes % Si

    $LMNL
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Liminal BioSciences Reports Fourth Quarter and Year Ended 2022 Financial Results

    CTA-enabling work on track to seek approval to commence Phase 1 clinical trial of LMNL6511 during the second half of 2023Addition of GPR40 agonist discovery program aiming for the development of a novel liver-safe GPR40 agonist for the treatment of type 2 diabetes Closed December 31, 2022 with just over CAD 37 million cash on hand, expecting to provide cash runway into early 2024Net loss from continuing operations of CAD 6.6 million during the quarter ended December 31, 2022 compared to CAD 8.8 million during the fourth quarter of 2021Regained compliance with minimum bid price requirement for continued listing on the Nasdaq Capital MarketCompleted the sale of a non-core real estate asset at

    $LMNL
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Liminal BioSciences Reports Third Quarter 2022 Financial Results and Business Highlights

    $40.8M of cash and cash equivalents at September 30, 2022 Discontinuation of fezagepras developmentTermination of legacy CDMO agreement for cash savings of $33.1 millionNet loss from continuing operations of $4.5 million during the quarter ended September 30, 2022 compared to $9.7 million net loss for the same period 2021Current cash runway is anticipated to support our near-term development goals into the fourth quarter of fiscal 2023Possibilities to sell non-core assets to further extend runway into 2024Changes to strengthen executive leadership teamLAVAL, QC and CAMBRIDGE, England, Nov. 9, 2022 /CNW/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today

    $LMNL
    Biotechnology: Pharmaceutical Preparations
    Health Care

$LMNL
Financials

Live finance-specific insights

See more
  • Liminal BioSciences to Report Fourth Quarter and Year Ended 2022 Financial Results on March 15, 2023

    LAVAL, QC, and CAMBRIDGE, England, March 13, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its fourth quarter and year ended 2022 financial results after market close on Wednesday March 15, 2023. Liminal will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Thursday March 16, 2023. To join the conference call without operator assistance, you may register and enter your phone number at https://bit.ly/3FeNJBk to receive an instant automated call back.

    $LMNL
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Liminal BioSciences to Report Third Quarter 2022 Financial Results on November 9, 2022

    LAVAL, QC and CAMBRIDGE, England, Nov. 8, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its third quarter 2022 financial results after market close on November 9, 2022. Liminal will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Thursday November 10, 2022. The telephone numbers to access the conference call are 888-205-6786 and 647-484-0474, using the following passcode: 722285. An audio replay of the call will be available as of Thursday November

    $LMNL
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Liminal BioSciences Reports Second Quarter 2022 Financial Results and Business Highlights

    $55.8M of cash and cash equivalents at June 30, 2022 Discontinuation of fezagepras developmentNet loss from continuing operations of $6.5 million during the quarter ended June 30, 2022 compared to $12.6 million during the quarter ended June 30, 2021LAVAL, QC and CAMBRIDGE, England , Aug. 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the second quarter ended June 30, 2022. Liminal BioSciences will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Wednesday August 10, 2022. The telephone numbers to access the conference call are 888-390-0620 and 416-764-8651. An a

    $LMNL
    Biotechnology: Pharmaceutical Preparations
    Health Care

$LMNL
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more